LOXL2 and neoplasm: In addition to PXS–S1C, several small molecule inhibitors were synthesized and shown both to inactivate LOXL2 (IC50 = 0.008–0.203 μM) and to repress the epithelial–to–mesenchymal transition (EMT), proliferation of tumor cells and progression of fibrosis [12,13,14,15,16,17].